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Abstract. Background: Tumour-derived microvesicles (TMVs)
may interact with cells of the immune system. Our previous
observations indicated that TMVs modulate production of
cytokines and reactive oxygen species (ROS) by monocytes.
This study was designed to determine the role of TMVs in
stimulation of chemokine production by human monocytes.
Materials and Methods: Chemokines at the mRNA and protein
level were detected by real-time PCR and by Western blot,
respecively. Chemokine release and chemotaxis of blood
leukocytes were analysed by flow cytometry. Matrigel assay
was used to determine angiogenesis in a NOD-SCID mice
model. Results: TMVs induced secretion of interleukin-8
(CXCL8), monocyte chemoattractant protein-1 (CCL2),
macrophage inflammatory protein-1α (CCL3) and MIP-1β
(CCL4), and regulated on activation normal T-cells expressed
and secreted (CCL5) chemokines and accumulation of their
mRNA in monocytes. Moreover, TMVs enhanced angiogenesis
in NOD-SCID mice by delivering chemokines and via
stimulation of monocytes. In addition, TMVs may be storage
for chemokines thus inducing chemotaxis of blood leukocytes.
Conclusion: These results further support the role of TMVs in
modulation of monocyte biological activity. 
Monocytes are a heterogeneous population of cells with
antigen-presenting, phagocytic and antimicrobial activities (1,
2). Their role in cancer is ambigious as they may produce pro-
and anti-tumour factors (3, 4). For example, contact of
monocytes with tumour cells in vitro leads to the production
by the former of tumour necrosis factor alpha (TNFα),
interleukin (IL)-10, IL-12, reactive nitrogen (RNS) and
oxygen species (ROS) (5, 6), and chemokines: IL-8 (CXCL8),
monocyte chemoattractant protein-1 (CCL2) and regulated on
activation normal T-cells expressed and secreted (CCL5) (7).
Monocytes recruited to the tumour microenviroment by
tumour-released growth factors (colony-stimulating factor-1,
CSF-1) and chemokines [CCL2, macrophage inflammatory
protein-1α (CCL3), macrophage inflammatory protein-1β
(CCL4), CCL5, monocyte chemoattractant protein-3 (CCL7)
and monocyte chemoattractant protein-2 (CCL8) (8-10)] give
rise to tumour-infiltrating macrophages (TIMs). TIMs are the
major component of leukocyte infiltrate of the tumour (4, 11)
and are ‘educated’ by the tumours to release immuno-
suppressive cytokines/chemokines (7, 8). Abundance of TIMs
in the tumour bed correlates with a poor prognosis in patients
with breast, prostate, ovarian and cervical cancer (12) and,
surprisingly, with good prognosis in colorectal cancer (13).
TIMs are a source of chemokines growth-related oncogene-α
(CXCL1), chemokines growth-related oncogene-β CXCL2,
CXCL8, CCL2, CCL5, macrophage inflammatory protein-4
(CCL18), macrophage-derived chemokine (CCL22) (14-16),
which contribute to tumour angiogenesis, enhance cell
adhesion and proliferation, and up-regulate metalloproteinases
(MMPs) secretion (11, 17, 18). In particular, CXCL8 shows
chemotactic activity for neutrophils, lymphocytes and
basophils (17). CCL2 is a major attractant for these cells (19).
TIMs interact not only with tumour but also with stromal cells
and extracellular matrix components (11). In addition, TIMs
in situ and circulating blood monocytes are exposed to
membrane microfragments released by tumour cells, known
as tumour-derived microvesicles (TMVs) (20). TMVs are
small, most less than 1 μm, circular or villi-like fragments of
tumour cell membrane (21). TMVs express cell surface
determinants such as β1, α3 and α5 integrins, HLA class I,
CD44, CD147 and chemokine receptors (CCR3, CCR6,
CXCR1), but their level differs from that of the cells they are
originated from (21-24). Activation of tumour cells leads to a
significantly higher release of TMVs (21, 25). The role of
TMVs in antitumour immune response is not fully understood.
Growing evidence suggests that TMVs have a potent
protumour activity, e.g. by inducing apoptosis of tumour-
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specific cytotoxic T-cells, generation of myeloid-derived
suppressor cells and by increasing chemoresistance of primary
tumours (26). On the other hand, TMVs may activate
monocytes to produce cytokines and ROS, which results in the
enhancement of their cytotoxic/cytostatic potential both in
vitro and in vivo (27). However, little is known of the role of
chemokines in the interactions of TMVs with monocytes. 
In the present study, we asked whether TMVs may
modulate chemokine production by monocytes in a similar
manner as tumour cells, and be a source or storage for
chemokines.
Materials and Methods
TMVs isolation. TMVs were obtained from the following human
cell lines: HPC-4 (pancreatic adenocarcinoma, TMVHPC), DeTa
(colorectal adenocarcinoma, TMVDeTa) and A549 (lung carcinoma,
TMVA549) as previously described (21). Cells were cultured by bi-
weekly passages in RPMI-1640 (Sigma, St. Louis, MO, USA) with
5% foetal bovine serum (FBS; PAA Laboratories, Pasching,
Germany) centrifuged at 50,000 ×g. Cell lines were regularly tested
for Mycoplasma sp. contamination by using PCR-ELISA kit
according to the manufacturer’s procedure (Roche, Mannheim,
Germany). Supernatants from confluent cell cultures were collected,
centrifuged at 2,000 ×g for 20 min to remove cell debris and then
centrifuged again at 50,000 ×g (RC28S; Sorvall, Newton, CT, USA)
for 1 h at 4˚C. Pellets were washed several times to remove FBS
and finally resuspended in serum-free medium. Quantification of
TMVs proteins was evaluated by the Bradford method (BioRad,
Hercules, CA, USA). TMVs were tested for endotoxin
contamination by the Limulus test according to the manufacturer’s
instruction (Charles River Laboratories, Inc., Wilmington, MA,
USA) and stored at –20˚C. For determination of chemotaxis, TMV
were labelled with PKH26 dye according to the manufacturer’s
protocol (Sigma).
Isolation of blood leukocytes. Blood leukocytes were isolated from
peripheral blood after hypotonic haemolysis of erythrocytes.
Lymphocytes, granulocytes and monocytes were distinguished by
FSC/SSC parameters during flow cytometric analysis (FACSCalibur).
Human peripheral blood mononuclear cells (PBMCs) were isolated
from EDTA-treated blood of healthy donors by the standard
Ficoll/Isopaque (Pharmacia, Uppsala, Sweden) density gradient
centrifugation. Monocytes were separated from PBMCs by counter-
flow centrifugal elutriation with a JE-6.B elutriation system equipped
with a 5 ml Sanderson separation chamber (Beckman, Palo Alto, CA,
USA), as previously described (6). Monocytes were suspended in
RPMI-1640 culture medium supplemented with L-glutamine and
gentamycin (25 μg/ml) (Sigma). Monocyte purity was more than
90%, as assessed by FACS analysis (FACSCalibur; BD Biosciences
Immunocytometry Systems, San Jose, CA, USA).
Expression of chemokine mRNA in monocytes and TMVs.
Monocytes (5×106) were incubated in low attachment tubes (BD
Falcon, Bedford, MA, USA) in serum-free medium alone or with
TMVs (30 μg/ml) for 2-4 h at 37˚C. Expression of chemokine
mRNA was determined by real-time PCR. The total RNA was
extracted from monocytes by the single-step isolation method using
TRI-ZOL reagent (Gibco-BRL, Grand Island, NY, USA) according
to the manufacturer’s protocol. The first-strand cDNA was obtained
from the total RNA samples (1 μg) with Moloney murine leukemia
virus (M-MLV) reverse transcriptase (Sigma) and oligo-dT (Sigma)
primer, as specified by the manufacturer’s protocol. The quantitative
PCR for CXCL8, CCL2, CCL3, CCL4 and CCL5 (TaqMan Gene
Expression Assays; Applied Biosystems, Foster City, CA, USA) was
performed using the 7300 Real-Time PCR System (Applied
Biosystems). The fluorescent signals generated during the
informative log-linear phase were used to calculate the relative
amount of mRNA. β-Actin (ACTB) was used as control for each
PCR run and the mRNA expression was calculated as a fold
difference from that of untreated monocytes normalized by ACTB
results (2–ΔCT) Expression of chemokine mRNA in TMVs alone
was presented as a threshold cycle (CT) value. 
Western blot. TMV samples were lysed with M-Per buffer (Pierce,
Rockford, IL, USA) containing inhibitors of proteases, as described
elsewhere (21). Samples (50 μg) were then treated for 4 min at 95°C
in sodium dodecyl sulfate (SDS) reducing buffer containing β-
mercaptoethanol, followed by SDS-polyacrylamide gel
electrophoresis (12% polyacrylamide gels) and transferred onto
polyvinylidene difluoride (PVDF) 2 μm membrane (Immune-blot
PVDF; BioRad, Hercules, CA, USA). The membranes were blocked
for 1 h at room temperature in TBS-0.1% Tween with 1% bovine
serum albumin (BSA; Sigma). Next, the membranes were incubated
overnight at 4˚C in TBS-Tween-BSA with the following antibodies:
rabbit anti-human CXCL8, mouse anti-human CCL5, CCL3 (Santa
Cruz Biotech, Santa Cruz, CA, USA), goat anti-human CCL2 (R&D
Systems Minneapolis, MN, USA), rabbit anti-human GAPDH (Cell
Signaling Systems, Beverly, MA, USA). The membranes were
washed in TBS-Tween-BSA and incubated with rabbit anti-goat,
rabbit anti-mouse or goat anti-rabbit secondary antibody conjugated
with horseradish peroxidase (dilution 1:2,000). All antibodies were
purchased from Sigma. The protein bands were visualized with the
SuperSignal West Pico Chemiluminescence Substrate kit, as
recommended by the manufacturer (Pierce) and analysed with
KODAK GEL LOGIC 1500 Digital Imaging System (Kodak,
Rochester, NY, USA). 
Determination of chemokine secretion by monocytes. Monocytes
(1×106/ml) were cultured with TMVs (30 μg/ml) in serum-free
RPMI-1640 medium at 37˚C, 5% CO2 and 95% humidity. After 
18 h of culture, supernatants were collected and concentrations of
chemokines (CCL2, CCL3, CCL4, CCL5, CXCL8) were measured
using FlexSet system (BD Biosciences) followed by flow cytometric
analysis (FACSCanto; BD Biosciences). Chemokines were also
detected in TMVs. For this purpose, 20 μg of intact TMVs and
TMVs lysed with M-Per buffer (Pierce, Rockford, IL, USA) were
analysed as described previously (21). The FlexSet beads were
discriminated in FL-4 and FL-5 channels, while the concentration
of specified chemokine was determined by the intensity of FL-2
fluorescence. The amount of chemokines was computed by using
the respective standard reference curve and FCAP Array software
(BD Biosciences). For all chemokines, the detection level was 10
pg/ml. In some experiments, supernatants were collected,
centrifuged (30 min at 50,000× g) and frozen for further chemotaxis
experiments. FlexSet results (for CXCL8, CCL5 and CCL3) were
confirmed by ELISA method (R&D Systems) according to the
manufacturer’s protocol.
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Matrigel matrix implants in NOD-SCID mice. The angiogenesis
assay was carried out by injecting 6 to 8 week old NOD-SCID mice
(CB-17/IcrCrl) in the abdominal midline with 100 μl of TMVs (30
μg/ml, TMVHPC, TMVA549, or TMVDeTa) mixed with 400 μl of
precooled Matrigel matrix (BD Falcon). Matrigel matrix alone was
used as background control. Human monocytes (1×106/mouse)
stimulated or not with TMVs (30 μg/ml, for 2 h) were implanted
into NOD-SCID mice in parallel. After 6 days, mice were
euthanased, and the Matrigel matrix was removed and placed in 500
μl BD Recovery Solution (BD Falcon) for the following 7 days. The
Matrigel matrix implants were then suspended in Drabkin’s solution
(Sigma) and after 30 min centrifuged. The content of haemoglobin
was determined by measuring absorbance at 540 nm in U-1800
spectrophotometer (Hitachi, Tokyo, Japan) (28). 
Determination of TMV-induced chemotaxis. Leukocytes were placed
in the upper chamber (2×105/per well) of Transwell 24-well plates
with 8 μm pore filter (Costar Corning, Cambridge, MA, USA).
PKH26-labelled TMVs (30 μg/ml) were resuspended in the lower
chamber in RPMI-1640 medium. In parallel, the same quantity of
lysed TMV were used. Chemotactic assay was performed for 2-4 h,
as described elsewhere (21). Cells from the lower chamber were
then scored using a FACSCalibur flow cytometer. The cells were
gated according to their FSC/SSC parameters and counted during a
20 s acquisition period at the high flow rate. Data are expressed as
the percentage of the cell input corrected by the percentage of cells
which migrated spontaneously to the medium.
Statistical analysis. Statistical analysis was performed by paired
Student’s t-test in all experiments, except mouse experiments, where
nonparametric Mann-Whitney test was used. Differences were
considered significant at p-values <0.05.
Results
TMVs contain chemokine and mRNA for chemokines. Studies
on chemokine content in TMVs by FlexSets revealed that
TMVA549 and TMVHPC contain CXCL8. The ELISA method
showed that intact TMVs contain less CXCL8 than lysed ones
(data not shown). As the ELISA method is not designed for
TMVs analysis, the presence of CXCL8 in TMVs was
confirmed by Western blot (Figure 1). In the case of TMVDeTa,
no chemokines were detected. At the mRNA level, TMVHPC
contained mRNA for ACTB (CT 28.49), CXCL8 (CT 33.24),
CCL2 (CT 34.65) and CCL5 (CT 34.36). HPC-4 cells expressed
mRNA for ACTB (CT 20.09), CXCL8 (CT 18.93), CCL2 (CT
28.32), CCL3 (CT 35.52), CCL4 (CT 33.98) and CCL5 (CT
26.32). TMVA549 had mRNA for ACTB (CT 31.69), CXCL8
(CT 25.31), CCL2 (CT 35.74), and CCL5 (CT 34.93). No
mRNA for CCL3 or CCL4 was detected in TMVHPC and
TMVA549. A549 cells expressed mRNA for ACTB (CT 19.21),
CXCL8 (CT 15.69), CCL2 (CT 22.48), CCL3 (CT 35.45), CCL4
(CT 32.18) and CCL5 (CT 32.09). In the case of TMVDeTa and
DeTa cells, no mRNA for chemokines was found.
TMVs induce production of chemokines in monocytes.
Monocytes were cultured with TMVs obtained from three
different tumour cell lines for 18 h and chemokine secretion
was analysed by FlexSets. All TMVs induced secretion of
CCL2, CCL3, CCL4, CCL5 and CXCL8 by monocytes
(Figure 2). The levels of secreted chemokines were lower
than those induced by the appropriate cell lines (not
shown). Only low amounts of CXCL8 (less than 20 pg/ml)
were found in TMVHPC and TMVA549. Since stimulation
of monocytes by different TMV was similar, for further
experiments, TMVHPC were chosen as being representative
for determination of mRNA expression. Increased
expression of mRNA for CXCL8 (21.69 fold; CT 16.55),
CCL2 (44.06-fold; CT 17.23), CCL3 (24.7-fold; CT 16.59),
CCL4 (54.95-fold; CT 13.17) and CCL5 (10.9-fold; CT
22.95) was found in monocytes after 2 h stimulation with
TMVHPC (Figure 3). Lower CT values for chemokine
mRNA in monocytes stimulated with TMVs in comparison
to those in TMVs alone (see above) indicated production of
tested chemokines in monocytes and not just a transfer of
mRNA by TMVs. 
TMVs induce angiogenesis. As CXCL8, which was detected
in TMVs, is an inducer of angiogenesis, the proangiogenic
potential of TMVs was tested using the Matrigel assay. All
tested TMVs induced angiogenesis, with the strongest effect
being exerted by TMVA549 (Figure 4). Monocytes alone
showed little angiogenic activity. However monocytes
preincubated with TMVs induced stronger angiogenesis than
monocytes or TMVs alone (Figure 5). A similar effect on
monocytes, as for TMVA549, was also observed for
TMVHPC and TMV DeTa used in the study.
TMVs induce chemotaxis of leukocytes. Previous
observation indicated that TMVs contain CXCL8.
Therefore, it was thought that TMVs may induce
chemotaxis of blood leukocytes. The chemotactic activity
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Figure 1. Expression of CXCL8 in TMVs from cell lines. A
representative Western blot out of two performed is presented. GAPDH
was used as a positive control.
of blood leukocytes towards TMVs was evaluated using
transwell assays. Cells were collected from the lower
transwell chambers, and their number was counted by
FACS according to FSC and SSC parameters during a 20 s
acquisition. The obtained data show that all tested TMVs
induced chemotaxis of leukocytes (Figure 6). However, the
strongest chemotaxis of granulocytes, lymphocytes and
monocytes was observed using TMVA549 as compared to
TMVHPC and TMVDeTa. Moreover, chemotaxis was twice
as strong when lysed TMVs were used in the assay,
especially in case of granulocytes and lymphocytes (data
not shown). 
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Figure 2. The secretion of chemokines by monocytes cultured alone (control) or stimulated with TMVs (30 μg/ml) after 18 h culture. The level of
chemokines in the culture supernatants was determined by FlexSet method. Data (mean±SD) from four independent experiments are presented.
*p<0.05 and **p<0.001 compared to the control. None of these chemokines were detected in TMV alone, except CXCL8.
Discussion 
The present study shows that TMVs play an important role in
monocyte–tumour cell interactions as they may induce
chemokine production by monocytes. In addition, TMVs may
act as a ‘storage pool’ for chemokines and chemokine mRNA. 
The interactions of monocytes (or TIMs) with tumour cells
are still not clear. Our previous data indicated that TMVs
induced production of cytokines and ROS by monocytes,
activated some signalling pathways that regulate cytokine
production, and increased antitumour response (27). This
study shows that TMVs may be involved in the chemokine
network between monocytes and tumour cells. The present
results show that monocytes stimulated with TMVs secreted
chemokines of the CXC (CXCL8) and CC (CCL2, CCL3,
CCL4 and CCL5) families. Accumulation of chemokine
mRNA in monocytes implicates their de novo synthesis.
Moreover, we previously showed that TMVs induce TNFα
secretion (27), which may, in turn, induce CXCL8
production. It was suggested that hyaluronan or other CD44
ligands carried by TMVs are involved in monocyte–TMV
interactions by analogy to monocyte–tumour cell interactions
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Figure 3. Fold increase in CXCL8, CCL2, CCL3, CCL4 and CCL5
mRNA expression in monocytes stimulated with TMVHPC (30 μg/ml) for
2 h as compared to control monocytes. Mean data of three experiments
performed by real-time PCR are presented. 
Figure 4. The effect of TMVs on angiogenesis in NOD-SCID mice
assessed by Matrigel matrix assay. Matrigel matrix alone (control) and
30 μg/ml of TMVDeTa or TMVHPC or TMVA549 with Matrigel matrix
were implanted into NOD-SCID mice. Haemoglobin content was
determined by absorbance at 540 nm. Results (mean±SD) from three
independent experiments are presented. *Significantly different (p<0.01)
from the control.
Figure 5. The effect of TMVs and monocytes (Mo) on angiogenesis in
NOD-SCID mice. Mo preincubated with TMVHPC for 2 h in vitro were
implanted with Matrigel matrix to NOD-SCID mice. Mo alone and
TMVHPC were used as controls. Haemoglobin content in excised
Matrigel is expressed as absorbance (at 540 nm) ±SD of three
independent experiments. *Significantly different (p<0.01) in
comparison to TMVHPC alone or control Mo.
Figure 6. Chemotactic response of human peripheral blood leukocytes to
TMVs (30 μg/ml) analysed by transwell assay. Data are expressed as
the percentage of the cell input number corrected by the percentage of
cells, which migrated spontaneously to the medium alone. Results
(mean±SD) from four independent experiments are presented.
(5, 27). This is in keeping with other data that hyaluronan
fragments induced secretion of CCL3, CCL4 and CCL5 by
macrophages (19) and CCL2, CXCL8 by mesothelial cells
(29). Tumour cells stimulate monocytes to secrete greater
amounts of chemokines, and the range of chemokines
produced was broader as it also included CXCL9 and
CXCL10 (data not shown).
The significance of the increased chemokine production
during monocyte–tumour interactions may be manifold.
First, chemokines secreted by monocytes seem to be
biologically active, as stronger angiogenesis was observed
when monocytes were preincubated with TMVs. These data
may suggest that contact of monocytes with TMVs results in
the release of proangiogenic factors, including chemokines
(CXCL8, CCL2 and CCL3). We concentrated on the role of
chemokines, as the secretion of vascular endothelial growth
factor in monocytes stimulated with TMVs is very low
(unpublished data), but we cannot exclude the role of other
proangiogenic factors (β-fibroblast growth factor, hepatocyte
growth factor, etc.) (30). On the other hand, TMVs alone did
induce angiogenesis which is in keeping with the findings of
others (31, 32). The strongest proangiogenic activity was
observed using TMVA549, and the weakest effect with
TMVDeTa. This is in keeping with ELISA/Western blot
results as TMVA549 and TMVHPC were found to contain
proangiogenic CXCL8 (18, 33).
As TMVs carry CXCL8 (protein and mRNA), it is not
surprising that granulocytes, which express CXCL8 receptors
(CXCR1, CXCR2) migrate to them. In contrast, TMVDeTa
did not contain any of the tested chemokines and induced the
weakest chemotaxis. Surprisingly, chemotaxis of monocytes
to TMVs was very weak. This may be because monocytes
move at a very low speed in comparison to granulocytes
(34), or the amount of chemokines in TMVs is too low to
induce stronger response of monocytes, as optimal
concentrations of chemokines to induce monocyte
chemotaxis are around 20 ng/ml (34). 
It is unknown exactly where chemokines are located in
TMVs, and whether they are released effectively. Perhaps
TMV-related chemokines do not create a concentration
gradient, resulting in impaired chemotaxis (23). When lysed
TMVs were used for chemotaxis, stronger response of all
leukocyte populations was observed (unpublished data),
suggesting that chemokines are present in TMVs albeit with
limited access. Apart from chemokines, TMVs may carry
other chemoatractants or proangiogenic factors, e.g. growth
factors, tetraspanins or ephrin-B1 (35), which should be
taken into consideration as well. It should be stressed that
although TMVDeTa did not contain chemokines, they were
still able to induce production of chemokines by
monocytes, which further supports the view that TMVs not
only transfer chemokines but are also inducers of their
production. 
It was previously mentioned that microvesicles may
transfer mRNA from embryonic stem cell and endothelial
progenitor cells to different target cells (36, 37). Now, we
show that TMVs may also carry chemokines and chemokine
mRNA which can probably be transported to target cells. 
In summary, evidence was provided that TMVs induce
secretion and production of chemokines by monocytes. In
addition, TMVs may be important modulators of the chemokine
network in the tumour microenvironment. This study
investigated TMV interactions with monocytes, but the effect of
TMVs on tumour cells should also be taken into consideration.
This investigation demonstrated for the first time that TMVs
may act as a storage pool for biologically active chemokines
and their mRNAs. Further investigations may elucidate the role
of TMVs in their interactions with tumour cell. 
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